Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Submitting institution
-
Imperial College of Science, Technology and Medicine
- Unit of assessment
- 12 - Engineering
- Output identifier
- 367
- Type
- D - Journal article
- DOI
-
10.1038/nm.3645
- Title of journal
- Nature Medicine
- Article number
- -
- First page
- 1043
- Volume
- 20
- Issue
- 9
- ISSN
- 1078-8956
- Open access status
- Out of scope for open access requirements
- Month of publication
- August
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
10.1038/nm.3645
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
14
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Alopecia Areata is a common autoimmune disease that results in hair loss. This work established the therapeutic potential of two drugs to treat the disease. The results were publicized by 23 news outlets including Science Daily, MPR, MedPage Today and NHS Choices. The results led to a Phase II clinical trial at Columbia University (12 patients, reference NCT02299297) with 9/12 patients having near-complete hair regrowth within 5 months of treatment. It also led to further clinical trials at Yale University (50 patients, references NCT02197455 and NCT02812342) and at Stanford University (40 patients, reference NCT02312882).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -